Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273882 · ClinicalTrials.gov registry record
An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 497
- Enrollment target
NCT02273882: Completed study, sponsored by AstraZeneca.
NCT02273882 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 497 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02273882 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 497 participants
- Enrollment target
Study Summary
Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.
Primary Outcome
A composite outcome of burden of illness (BOI) associated with hospitalization for RSV in terms of clinical, humanistic and health economic outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2016-08-19 |
What the finished NCT02273882 record still lists
NCT02273882 is an observational study that tracks outcomes without assigning an intervention. The registered 497 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02273882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02273882 about?
NCT02273882 is a clinical study titled "An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants". Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.
What is the current status of trial NCT02273882?
This trial is currently completed. The enrollment target is 497 participants. The study started on 2014-11-17. Estimated completion is 2016-08-19.
Who is sponsoring clinical trial NCT02273882?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- NCT05766670 · 497 participants · Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI